Esuberaprost (United Therapeutics) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor. PGI2 agonists are potent vasodilators and platelet aggregation inhibitors, and also help relax smooth muscle cells by counteracting the effect of vasoconstrictive mediators.
United Therapeutics has ceded a large advantage in the time required to develop and formulate esuberaprost as an oral prostacyclin. The pulmonary hypertension (PH) market now contains both Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) and Orenitram (treprostinil; United Therapeutics) to occupy the oral prostacyclin niche, leaving esuberaprost a much narrower potential indication to be used as an adjunctive to inhaled Tyvaso (treprostinil; United Therapeutics/Mochida). This narrow therapeutic role, combined with questions surrounding esuberaprost’s efficacy, leaves the drug with restricted commercial potential
LIST OF FIGURES
10 Figure 1: Esuberaprost for pulmonary hypertension – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of esuberaprost for pulmonary hypertension
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of esuberaprost for pulmonary hypertension
14 Figure 4: Esuberaprost sales for pulmonary hypertension in the US, 2016–25
LIST OF TABLES
5 Table 1: Esuberaprost drug profile
7 Table 2: Esuberaprost Phase II data in pulmonary arterial hypertension
10 Table 3: Esuberaprost Phase III trials in pulmonary arterial hypertension
15 Table 4: Esuberaprost sales for pulmonary hypertension in the US ($m), 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.